[8-K] Aptose Biosciences, Inc. Reports Material Event

Rhea-AI Filing Summary

Filing date: August 6, 2025. Aptose Biosciences, Inc. (APTO) filed a Form 8-K reporting a Regulation FD disclosure announcing a press release dated August 6, 2025, which is attached as Exhibit 99.1.

Regulatory note: The press release attached as Exhibit 99.1 is explicitly stated to not be deemed "filed" for purposes of Section 18 of the Exchange Act pursuant to General Instruction B.2. Item 9.01 lists Exhibit 99.1 (Press Release dated August 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Company details: Commission File No. 001-32001; EIN 98-1136802; principal executive office at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada; phone (647) 479-9828. No securities are registered under Section 12(b). The form is signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer, dated August 6, 2025.

Insights

Securities Analyst

TL;DR: Routine Form 8-K disclosing a press release (Exhibit 99.1); materiality appears limited absent press release content.

This 8-K notifies investors that Aptose issued a press release on August 6, 2025, attached as Exhibit 99.1, and includes an iXBRL cover page as Exhibit 104. The filing follows Regulation FD disclosure protocols and expressly states the press release is not "filed" under Section 18 per General Instruction B.2. Because the substantive content of the press release is not included in the 8-K text provided, investors must review Exhibit 99.1 for any material operational or financial information.

Impact assessment: not impactful given the absence of disclosed substance in the 8-K itself.

Corporate Governance Expert

TL;DR: Administrative compliance filing confirming a Reg FD release; procedural disclosure, not a standalone material event.

The filing documents compliance with Regulation FD by attaching a press release as Exhibit 99.1 and clarifies its filing status under General Instruction B.2. It lists corporate identifiers (Commission File No. and EIN), principal office address, and indicates no registered securities under Section 12(b). The 8-K is signed by the CEO, William G. Rice, Ph.D., and bears the August 6, 2025 date.

Impact assessment: not impactful for governance or control issues based solely on this filing.

False000088236100008823612025-08-062025-08-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 6, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 6, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit Number		Description
99.1		Press Release dated August 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: August 6, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose (APTO) file on August 6, 2025?

Aptose filed a Form 8-K reporting a Regulation FD disclosure and attaching a press release as Exhibit 99.1 dated August 6, 2025.

Is the attached press release considered "filed" under the Exchange Act?

No. The 8-K states the press release attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act pursuant to General Instruction B.2.

Which exhibits are listed in Item 9.01 of the 8-K?

Item 9.01 lists Exhibit 99.1 (Press Release dated August 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Who signed the Form 8-K for Aptose?

The Form 8-K is signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer, dated August 6, 2025.

Where is Aptose's principal executive office?

The principal executive office is listed as 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada; phone (647) 479-9828.

Are any securities registered under Section 12(b) per this filing?

No. The filing lists None under securities registered pursuant to Section 12(b) of the Act.